Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:GTBP NASDAQ:SXTP NASDAQ:TVRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.73+2.1%$0.78$0.51▼$1.45$18.47M0.61111,816 shs12,368 shsGTBPGT Biopharma$0.49+3.8%$0.42$0.26▼$2.86$17.01M0.841.23 million shs1.41 million shsSXTP60 Degrees Pharmaceuticals$1.68-1.8%$1.54$1.22▼$10.77$4.55M2.47134,161 shs30,576 shsTVRDTvardi Therapeutics$2.01-0.5%$3.05$1.50▼$43.65$18.95M0.39390,829 shs74,864 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%+1.39%+1.43%-19.56%-13.48%GTBPGT Biopharma0.00%+10.75%+8.11%+6.02%-83.06%SXTP60 Degrees Pharmaceuticals0.00%+6.21%+20.42%-3.93%-82.15%TVRDTvardi Therapeutics0.00%+34.67%-30.10%-32.21%-91.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.73+2.1%$0.78$0.51▼$1.45$18.47M0.61111,816 shs12,368 shsGTBPGT Biopharma$0.49+3.8%$0.42$0.26▼$2.86$17.01M0.841.23 million shs1.41 million shsSXTP60 Degrees Pharmaceuticals$1.68-1.8%$1.54$1.22▼$10.77$4.55M2.47134,161 shs30,576 shsTVRDTvardi Therapeutics$2.01-0.5%$3.05$1.50▼$43.65$18.95M0.39390,829 shs74,864 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%+1.39%+1.43%-19.56%-13.48%GTBPGT Biopharma0.00%+10.75%+8.11%+6.02%-83.06%SXTP60 Degrees Pharmaceuticals0.00%+6.21%+20.42%-3.93%-82.15%TVRDTvardi Therapeutics0.00%+34.67%-30.10%-32.21%-91.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00BuyN/AN/AGTBPGT Biopharma 1.00SellN/AN/ASXTP60 Degrees Pharmaceuticals 2.00Hold$13.85724.40% UpsideTVRDTvardi Therapeutics 2.50Moderate Buy$39.801,880.10% UpsideCurrent Analyst Ratings BreakdownLatest SXTP, TVRD, AEON, and GTBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026SXTP60 Degrees Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/8/2026TVRDTvardi Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.005/27/2026AEONAEON Biopharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/22/2026SXTP60 Degrees Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.20 ➝ $3.705/20/2026SXTP60 Degrees Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral4/10/2026GTBPGT Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026TVRDTvardi Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026SXTP60 Degrees Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$11.20 ➝ $4.20(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/AGTBPGT BiopharmaN/AN/A$0.02 per share31.54$0.23 per shareN/ASXTP60 Degrees Pharmaceuticals$1.41M3.17N/AN/A($5.85) per share-0.29TVRDTvardi Therapeutics$7.14M2.64N/AN/A$2.23 per share0.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M-$5.004.06N/AN/AN/AN/A-994.63%8/11/2026 (Estimated)GTBPGT Biopharma-$28.35M-$6.33N/AN/AN/AN/AN/A-102.03%8/13/2026 (Estimated)SXTP60 Degrees Pharmaceuticals-$7.36M-$8.92N/AN/AN/A-574.91%N/A-131.48%8/12/2026 (Estimated)TVRDTvardi Therapeutics-$18.21M-$3.10N/AN/AN/AN/A-64.17%-43.90%N/ALatest SXTP, TVRD, AEON, and GTBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026GTBPGT Biopharma-$0.08-$0.11-$0.03-$0.11N/AN/A5/15/2026Q1 2026SXTP60 Degrees Pharmaceuticals-$0.76-$1.28-$0.52-$1.28$0.44 million$0.16 million5/8/2026Q1 2026TVRDTvardi Therapeutics-$0.65-$0.73-$0.08-$0.73N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/ASXTP60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ATVRDTvardi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22GTBPGT BiopharmaN/A4.144.14SXTP60 Degrees PharmaceuticalsN/A3.342.85TVRDTvardi TherapeuticsN/A2.252.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%GTBPGT Biopharma8.15%SXTP60 Degrees Pharmaceuticals7.96%TVRDTvardi Therapeutics44.66%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma9.40%GTBPGT Biopharma3.40%SXTP60 Degrees Pharmaceuticals1.69%TVRDTvardi Therapeutics7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma525.30 million74.37 millionNot OptionableGTBPGT Biopharma836.06 million34.84 millionNo DataSXTP60 Degrees Pharmaceuticals32.66 million2.61 millionNot OptionableTVRDTvardi Therapeutics809.38 million8.69 millionN/ASXTP, TVRD, AEON, and GTBP HeadlinesRecent News About These CompaniesTvardi Therapeutics (NASDAQ:TVRD) Trading 2.6% Higher - What's Next?July 2, 2026 | americanbankingnews.comTVRD Share News TodayJune 29, 2026 | uk.investing.comTvardi Therapeutics Sets Key Deadlines for 2026 MeetingJune 27, 2026 | theglobeandmail.comTvardi Therapeutics, Inc. Common StockJune 27, 2026 | fxempire.comFH.C. Wainwright Initiates a Buy Rating on Tvardi Therapeutics (TVRD)June 25, 2026 | theglobeandmail.comTvardi Therapeutics Shareholders Approve Directors and Governance MeasuresJune 11, 2026 | tipranks.comTvardi Therapeutics to Participate in Upcoming Investor EventsMay 21, 2026 | globenewswire.comOppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)May 13, 2026 | theglobeandmail.comTvardi Therapeutics (TVRD) Receives a Buy from BTIGMay 11, 2026 | theglobeandmail.comTvardi: Q1 Earnings SnapshotMay 8, 2026 | wtop.comWTvardi Therapeutics Announces First Quarter 2026 Results and Provides Business UpdateMay 8, 2026 | globenewswire.comBarclays downgrades Tvardi Therapeutics (TVRD)April 21, 2026 | msn.comTvardi Therapeutics (TVRD) Price Target Decreased by 43.91% to 8.50April 9, 2026 | msn.comBarclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD)April 8, 2026 | theglobeandmail.comTvardi Therapeutics to Participate in the Raymond James Biotech Innovation SymposiumApril 2, 2026 | globenewswire.comTvardi: Q4 Earnings SnapshotApril 1, 2026 | stamfordadvocate.comSTvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business UpdateMarch 31, 2026 | globenewswire.comTvardi Therapeutics to Participate in Upcoming Investor ConferencesFebruary 12, 2026 | markets.businessinsider.comWe're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn RateFebruary 7, 2026 | finance.yahoo.comTvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSXTP, TVRD, AEON, and GTBP Company DescriptionsAEON Biopharma NASDAQ:AEON$0.73 +0.01 (+2.08%) Closing price 04:00 PM EasternExtended Trading$0.74 +0.01 (+1.64%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.GT Biopharma NASDAQ:GTBP$0.49 +0.02 (+3.82%) Closing price 04:00 PM EasternExtended Trading$0.48 -0.01 (-2.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.60 Degrees Pharmaceuticals NASDAQ:SXTP$1.68 -0.03 (-1.75%) Closing price 04:00 PM EasternExtended Trading$1.68 +0.01 (+0.30%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.Tvardi Therapeutics NASDAQ:TVRD$2.01 -0.01 (-0.50%) Closing price 04:00 PM EasternExtended Trading$2.00 0.00 (-0.25%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
